SCHEMBL4671561

SCHEMBL4671561

O=C(C=C(O)c1nn[nH]n1)c1cc(C(=O)c2ccccc2)n(S(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
PKM P14618 1/20 0.33
CMA1 P23946 1/20 0.32
ALDH3A1 P30838 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
CYP2C19 P33261 1/20 0.32
FLT1 P17948 1/20 0.31
FLT4 P35916 1/20 0.31
KDR P35968 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
C5AR1 P21730 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PTGS2 P35354 1/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678102 0.93 CA2 (0.35) CA2CA9PKMCMA1ALDH3A1
SCHEMBL4672034 0.91 PTGDR2 (0.34) ALDH3A1CYP2C19PTGS2MMP3MMP8
SCHEMBL4673202 0.91 CA2 (0.34) CA2CA9PKMCMA1CYP2C19
SCHEMBL4675352 0.87 CMA1 (0.34) CA2CA9PKMCMA1CYP2C19
SCHEMBL4671838 0.85 CA2 (0.35) CA2CA9PKMCMA1ALDH3A1
SCHEMBL4674175 0.84 PTGDR2 (0.34) ALDH3A1CYP2C19PTGS2MMP3MMP8
SCHEMBL4676526 0.81 KMT2A (0.32) CYP2C19CXCR3MMP3MMP8
SCHEMBL4674121 0.81 TBXA2R (0.39) CA2CA9ALDH3A1PSEN1PSEN2
SCHEMBL4672248 0.80 RAPGEF4 (0.39) CA2CA9PKMALDH3A1PSEN1
SCHEMBL5899366 0.78 CA2 (0.35) CA2CA9PKMCMA1ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CA2 2384/4885CA9 2025/4885PKM 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.